Page last updated: 2024-11-04

aspartame

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID134601
CHEMBL ID171679
CHEBI ID2877
SCHEMBL ID3636
MeSH IDM0001821

Synonyms (172)

Synonym
MLS001066421
smr000471870
asp-phe methyl ester
AC-12293
e 951
sanecta
aspartamum
aminosweet
CHEBI:2877 ,
aspartam
aspartamo
3-amino-n-(alpha-carboxyphenethyl)succinamic acid n-methyl ester, stereoisomer
nutrasweet
methyl aspartylphenylalanate
sweet dipeptide
equal
dipeptide sweetener
l-phenylalanine, l-alpha-aspartyl-, 2-methyl ester
l-phenylalanine, n-l-alpha-aspartyl-, 1-methyl ester
3-amino-n-(alpha-carboxyphenethyl)succinamic acid n-methyl ester
ccris 5456
succinamic acid, 3-amino-n-(alpha-carboxyphenethyl)-, n-methyl ester, stereoisomer
n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
aspartamo [inn-spanish]
1-methyl n-l-alpha-aspartyl-l-phenylalanine
methyl l-aspartyl-l-phenylalanine
1-methyl n-l-alpha-aspartyl-l-phenylalanate
sc 18862
hsdb 3915
methyl n-l-alpha-aspartyl-l-phenylalaninate
asp-phe-ome
aspartam [inn-french]
tri-sweet
canderel
aspartame, l,l-alpha-
aspartamum [inn-latin]
methyl l-alpha-aspartyl-l-phenylalanate
l-aspartyl-l-phenylalanine methyl ester
3-amino-n-(alpha-methoxycarbonylphenethyl) succinamic acid
aspartylphenylalanine methyl ester
einecs 245-261-3
methyl l-alpha-aspartyl-l-phenylalaninate
BSPBIO_003549
n-l-alpha-aspartyl l-phenylalanine 1-methyl ester
NCGC00091104-01
aspartame ,
22839-47-0
asp-phe methyl ester, >=98%
aspartame, analytical standard
DB00168
aspartame (nf/inn)
D02381
NCGC00095160-01
NCGC00091104-02
KBIO3_002839
SPBIO_001692
SPECTRUM2_001706
SPECTRUM3_001949
SPECTRUM1505306
MLS001306461
NCGC00091104-03
methyl aspartylphenylalanine
sc-18862 ,
methyl ester, aspartylphenylalanine
aspartylphenylalanine, methyl
HMS2093B05
A0997
h-asp-phe-ome
sladex
e951
zero-cal
ins-951
e-951
nsc-758953
CHEMBL171679
aspartame (e951)
ins no.951
pal sweet
HMS1922B16
7421-84-3
(3s)-3-amino-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
NCGC00091104-04
cas-22839-47-0
NCGC00256407-01
dtxsid0020107 ,
tox21_302965
dtxcid20107
tox21_202315
NCGC00259864-01
A816383
3-amino-4-[(1-carboxy-2-phenyl-ethyl)-methyl-amino]-4-oxo-butanoic acid;n-l-alpha-aspartyl-l-phenylalanine methyl ester
nsc758953
pharmakon1600-01505306
tox21_111459
tox21_111080
AKOS015920055
HMS2233D15
CCG-39444
aspartame [usan:inn:ban:nf]
nsc 758953
unii-z0h242bbr1
z0h242bbr1 ,
n-(l-a-aspartyl)-l-phenylalanine methyl ester
NCGC00091104-05
n-l-alpha-aspartyl-l-phenylalanine methyl ester
AM20060556
aspartame [who-dd]
l-aspartyl-l-phenylalanyl methyl ester
aspartame [ep monograph]
aspartame [usan]
aspartame [fcc]
aspartame [inn]
aspartame [mart.]
aspartame [ii]
aspartame [fhfi]
aspartame [hsdb]
l-phenylalanine, n-l-.alpha.-aspartyl-, 1-methyl ester
aspartame [inci]
aspartame [usp-rs]
aspartame [mi]
aspartame [vandf]
(s)-3-amino-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic acid
EPITOPE ID:164026
AM84801
S2036
HY-B0361
SCHEMBL3636
tox21_111080_1
NCGC00095160-03
aspartyl-phenylalanine methyl ester
IAOZJIPTCAWIRG-QWRGUYRKSA-N
alpha-l-aspartyl-l-phenylalanine methyl ester
alpha-aspartyl-phenylalanine methyl ester
mfcd00002724
J-502447
(s)-3-amino-n-((s)-1-methoxycarbonyl-2-phenyl-ethyl)-succinamic acid
l-aspartyl-l-phenyl-alanine methyl ester
(s)-3-amino-4-((s)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-4-oxobutanoic acid
AB00376622_08
AB00376622_09
l-alpha-aspartyl-l-phenylalanine 2-methyl ester
(3s)-3-amino-3-{[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl}propanoic acid
l-aspartyl-l-phenylalanine methyl ester, 96%
aspartame, european pharmacopoeia (ep) reference standard
apm;canderel;l-alpha-aspartyl-l-phenylalanine-methylester;(s)-3-amino-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic acid
asp-phe methyl ester, >=99.0% (hplc)
aspartame, united states pharmacopeia (usp) reference standard
palsweet diet
l-aspartyl-l-3-phenylalanine methyl ester
SR-05000001682-1
sr-05000001682
aspartame, pharmaceutical secondary standard; certified reference material
SBI-0206757.P001
SW219179-1
tert-butyln-(3-formylphenyl)carbamate
aspartame 1000 microg/ml in methanol
AS-13889
Q182040
BRD-K78841970-001-06-2
(s)-3-amino-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoicacid
(3s)-3-amino-4-{[(1s)-1-benzyl-2-methoxy-2-oxoethyl]amino}-4-oxobutanoic acid
succinamin acid, 3-amino-n-(alpha-carboxyphenylethyl)-, n-methyl ester, stereoisomer
(3s)-3-amino-4-
aspartame (usp-rs)
53906-69-7
methylaspartylphenylalnate
aspartame (ep monograph)
aspartame (ii)
aspartame (mart.)
aspartyl phenylamine methyl ester
dipeptide sweetner
l-d-aspartyl-l-phenylalanine methyl ester

Research Excerpts

Toxicity

Aspartame is a structural analogue of both OTA and phenylalanine. Since 1981, when aspartame was first approved by the US Food and Drug Administration, researchers have debated both its recommended safe dosage (40 mg/kg/d) and its general safety to organ systems. Acute, subacute and chronic toxicity studies with as partame, and its decomposition products, conducted in mice, rats, hamsters and dogs have consistently found no adverse effect of aspartAME with doses up to at least 4000 mg/kg bw/day.

ExcerptReferenceRelevance
" Even with high doses, the metabolites of this sweetener do not accumulate in toxic amounts."( Clinical safety of aspartame.
Yost, DA, 1989
)
0.28
" Overall, the results suggest that aspartame may have adverse effects when intraperitoneally injected but not when the route of administration is oral."( Behavioral assessment of the toxicity of aspartame.
Holder, MD; Yirmiya, R, 1989
)
0.28
"This report examines the safety issues related to the nutritive sweetener aspartame, including possible toxic effects of aspartame's component amino acids, aspartic acid and phenylalanine, and its major decomposition products, methanol and diketopiperazine, and the potential synergistic effect of aspartame and dietary carbohydrate on brain neurochemicals."( Aspartame. Review of safety issues. Council on Scientific Affairs.
, 1985
)
0.27
" A slight decrease in serum cholesterol and an increase in relative spleen weight appeared to be without adverse effect."( Toxicity of aspartame and its diketopiperazine for Wistar rats by dietary administration for 104 weeks.
Fujimoto, T; Ishii, H; Koshimizu, T; Usami, S, 1981
)
0.26
" To reduce or abolish the OTA-induced toxic effects, several mechanisms were investigated."( Prevention of nephrotoxicity of ochratoxin A, a food contaminant.
Baudrimont, I; Betbeder, AM; Creppy, EE, 1995
)
0.29
" An attempt to prevent its toxic effect, mainly the inhibition of protein synthesis, has been made using aspartame (L-aspartyl-L-phenylalanine methyl ester) a structural analogue of both OTA and phenylalanine."( Reduction of the ochratoxin A-induced cytotoxicity in Vero cells by aspartame.
Baudrimont, I; Betbeder, AM; Creppy, EE, 1997
)
0.3
" The combination of these basic mechanisms with the unusual long plasma half-life time (35 days in non-human primates and in humans), the metabolisation of OTA into still active derivatives and glutathione conjugate both potentially reactive with cellular macromolecules including DNA could explain the multiple toxic effects, cytotoxicity, teratogenicity, genotoxicity, mutagenicity and carcinogenicity."( How aspartame prevents the toxicity of ochratoxin A.
Baudrimont, I; Creppy, EE, 1998
)
0.3
" Although the use of single food additives at their regulated concentrations is believed to be relatively safe in terms of neuronal development, their combined effects remain unclear."( Synergistic interactions between commonly used food additives in a developmental neurotoxicity test.
Howard, CV; Lau, K; McLean, WG; Williams, DP, 2006
)
0.33
" Acute, subacute and chronic toxicity studies with aspartame, and its decomposition products, conducted in mice, rats, hamsters and dogs have consistently found no adverse effect of aspartame with doses up to at least 4000 mg/kg bw/day."( Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies.
Burdock, GA; Doull, J; Kroes, RM; Magnuson, BA; Marsh, GM; Pariza, MW; Spencer, PS; Waddell, WJ; Walker, R; Williams, GM, 2007
)
0.34
" These results suggest that aspartame and saccharin could be toxic to the human circulation system as well as embryonic development via impairment of lipoprotein function."( Modified high-density lipoproteins by artificial sweetener, aspartame, and saccharin, showed loss of anti-atherosclerotic activity and toxicity in zebrafish.
Cho, KH; Choi, I; Kim, J; Kim, JY; Park, KH, 2015
)
0.42
" Since 1981, when aspartame was first approved by the US Food and Drug Administration, researchers have debated both its recommended safe dosage (40 mg/kg/d) and its general safety to organ systems."( Revisiting the safety of aspartame.
Choudhary, AK; Pretorius, E, 2017
)
0.46
" Although its consumption is considered to be safe in acceptable daily intake ranges which were set by the United States Food and Drugs Administration and other regulatory agencies, there are lots of controversies regarding its safety nowadays."( Nephrotoxic Effect of Aspartame as an Artificial Sweetener: a Brief Review.
Ardalan, MR; Ebrahimzadeh Attari, V; Malek Mahdavi, A; Tabibi, H, 2017
)
0.46
" In conclusion, these results suggested that NAC combined with FA can ameliorate the toxic effect of ASP on the rat's cerebral cortex."( The possible protective effect of N-acetyl-L-cysteine and folic acid in combination against aspartame-induced cerebral cortex neurotoxicity in adult male rats: a light and transmission electron microscopic study.
Abd-Ellah, HF; Abou-Zeid, NRA; Nasr, NM,
)
0.13
" Although clinical and epidemiological data revealed the link between the chronic overconsumption of ASs and adverse health effects, there still exist controversies over the potential adverse neural toxic effect of ASs such as aspartame (APM), with acceptable daily intake (ADI) for a long time, on human health."( Zebrafish Behavioral Phenomics Links Artificial Sweetener Aspartame to Behavioral Toxicity and Neurotransmitter Homeostasis.
Dong, G; Du, L; Han, G; Li, M; Li, X, 2021
)
0.62
" However, there is little evidence available about the nature and mechanisms of the adverse effects of long-term consumption of ASP on the cardiovascular system."( Long-term intake of aspartame-induced cardiovascular toxicity is reflected in altered histochemical parameters, evokes oxidative stress, and trigger P53-dependent apoptosis in a mouse model.
Anbara, H; Darya, GH; Kian, M; Sheibani, MT, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The sizes of the differences were modest implying that there is no need on pharmacokinetic grounds for a change in the ADI for older people."( Aspartame pharmacokinetics - the effect of ageing.
Abrams, SM; Heybroek, WM; Jackson, SH; Johnston, A; Maskrey, V; Puthrasingam, S; Swift, CG; Turner, P, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
"Aspartame (L-aspartyl-L-phenylalanine methyl ester) was given in capsules or solution to compare the bioavailability of its constituent amino acids, aspartate and phenylalanine."( Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution.
Burns, TS; Hurwitz, A; Stargel, WW, 1990
)
0.28
" In tracheostomized dogs, both formulations showed comparable pharmacokinetic parameters including Cmax, Tmax, AUC0-12 and bioavailability (F%), indicating that the taste-masking excipients do not have an effect on lung absorption of leuprolide acetate."( Pulmonary peptide delivery: effect of taste-masking excipients on leuprolide suspension metered-dose inhalers.
Adjei, AL; Barber, TE; Fulu, MY; Lee, DY; Zheng, JY, 2001
)
0.31
" The findings suggest that only foods with a relatively fast glucose absorption rate are able to significantly enhance the encoding and long-term retention of novel memory materials in healthy young adults."( The influence of fat co-administration on the glucose memory facilitation effect.
Durlach, P; Foster, JK; Perez, C; Sünram-Lea, SI, 2004
)
0.32
"Co-amorphous drug delivery systems are a promising approach to improve the dissolution rate and therefore potentially the oral bioavailability of poorly-water soluble drugs."( Aspartame as a co-former in co-amorphous systems.
Grohganz, H; Knuhtsen, A; Löbmann, K; Pedersen, DS; Rades, T; Schnitzkewitz, J; Wu, W, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Salmon calcitonin (sCT) could realize both requirements, however, it is limited by the low bioavailability caused by fibrillation."( Supramolecular nanoassemblies of salmon calcitonin and aspartame for fibrillation inhibition and osteogenesis improvement.
Li, J; Liu, Y; Sun, H; Xie, J; Xu, X; Xu, Z; Yu, P; Zhai, X, 2021
)
0.62

Dosage Studied

Aspartame is a suitable dosage form for blinded clinical studies, provided that the slower rate of absorption of phenylalanine from capsules is taken into account. Results suggest that aspartame, in acute dosage of approximately 50 mg/kg, is no more likely than placebo to cause seizures.

ExcerptRelevanceReference
" Individuals were randomly assigned in a double-blind design to aspartame or sucrose in each of five age groups; dosage levels were assigned according to age and weight groups."( Use of aspartame by apparently healthy children and adolescents.
Frey, GH, 1976
)
0.26
" Maximal plasma PHE and TYR concentrations were observed within 1 h after dosing and returned to baseline within 4-8 h in both species regardless of the dose of APM."( Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame.
Brisson, J; Dickie, BC; Dudley, RE; Hjelle, JJ; Kotsonis, FN; Marietta, MP; Sanders, PG, 1992
)
0.28
" Sprague-Dawley male rats (250-300 g) were dosed orally with aspartame (500 or 1000 mg/kg), phenylalanine (281 or 562 mg/kg), or tyrosine (309 or 618 mg/kg), and their behavior was analyzed 1 hr after dosing."( No change in spontaneous behavior of rats after acute oral doses of aspartame, phenylalanine, and tyrosine.
Kernan, WJ; Mullenix, PJ; Schunior, A; Tassinari, MS, 1991
)
0.28
" Plasma amino acid concentrations were determined after dosing and the molar plasma phenylalanine (Phe) to large neutral amino acid (LNAA) ratio calculated."( Aspartame ingestion with and without carbohydrate in phenylketonuric and normal subjects: effect on plasma concentrations of amino acids, glucose, and insulin.
Bell, EF; Brummel, MC; Filer, LJ; Krause, WL; Persoon, TJ; Stegink, LD; Wolf-Novak, LC; Ziegler, EE, 1990
)
0.28
" Thus, given the small effect on phenylalanine Cmax and Phe/LNAA and no effect on the extent of absorption of phenylalanine, aspartame ingested in capsules at doses up to 20 mg/kg is a suitable dosage form for blinded clinical studies, provided that the slower rate of absorption of phenylalanine from capsules is taken into account."( Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution.
Burns, TS; Hurwitz, A; Stargel, WW, 1990
)
0.28
" Memory was tested at 2 and 24 hours after dosage based on recall of standardized 16-item word lists."( The neuropsychiatric effects of aspartame in normal volunteers.
Goddard, JE; Greenblatt, DJ; Harmatz, JS; Lapierre, KA; Shader, RI, 1990
)
0.28
" Unfasted male CD-1 mice were dosed orally with 13, 130, or 650 mg/kg ASM in corn oil, while control animals received corn oil alone."( Neurobiochemical alterations induced by the artificial sweetener aspartame (NutraSweet).
Coulombe, RA; Sharma, RP, 1986
)
0.27
" In a second series of studies, young male and female rats were dosed with 1,000 mg/kg of aspartame on day 3-13 or 21-35 of age."( Oral administration of aspartame is not proconvulsant in rats.
Hong, JS; Sobotka, TJ; Thai, L; Tilson, HA; Zhao, D, 1989
)
0.28
" Data from these studies are in general agreement that aspartame at dosage levels below 1,000 mg/kg, or phenylalanine at equimolar doses, is without an effect on seizure susceptibility in animals."( Pharmacological effects of phenylalanine on seizure susceptibility: an overview.
Sze, PY, 1989
)
0.28
" The high mean plasma phenylalanine level after repeated APM dosing (13."( Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in individuals heterozygous for phenylketonuria.
Baker, GL; Bell, EF; Brummel, MC; Filer, LJ; Krause, WL; Stegink, LD; Ziegler, EE, 1989
)
0.28
" In subacute dosing experiments aspartame was included in the diet."( Effects of aspartame and carbohydrate administration on human and rat plasma large neutral amino acid levels and rat brain amino acid and monoamine levels.
Casacci, F; De Marchi, F; Esteve, A; Lomuscio, G; Mennini, T; Pacei, T; Romano, M; Salmona, M, 1989
)
0.28
" Aspartame dosing significantly increased both the mean peak plasma phenylalanine concentration and the plasma phenylalanine AUC value in proportion to dose."( Effect of aspartame loading on plasma and erythrocyte free amino acid concentrations in one-year-old infants.
Baker, GL; Filer, LJ; Stegink, LD, 1983
)
0.27
" Likewise, APM at the same dosage did not significantly affect gastric ulceration induced by nineteen hours of pylorus-ligation."( The biological properties of aspartame. II. Actions involving the gastrointestinal system.
Bianchi, RG; Cook, DL; Muir, ET; Nutting, EF,
)
0.13
" Results suggest that aspartame, in acute dosage of approximately 50 mg/kg, is no more likely than placebo to cause seizures in individuals who reported that their seizures were provoked by aspartame consumption."( Aspartame and seizure susceptibility: results of a clinical study in reportedly sensitive individuals.
French, JA; Luciano, D; Rowan, AJ; Shaywitz, BA; Sullivan, CM; Tuchman, L, 1995
)
0.29
"Acute dosing studies of aspartame, known commercially as "NutraSweet," have failed to demonstrate any neuropsychological changes that would imply performance decrements in flight operations."( Effects of alcohol and chronic aspartame ingestion upon performance in aviation relevant cognitive tasks.
Banich, MT; Belger, A; Bernadine, E; Stokes, AF, 1994
)
0.29
" Collagen with the characteristic striped pattern matured normally in control samples, such as those not dosed with amyloid precursors or those treated with a non-amyloidogenic Bence-Jones protein (e."( Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Edmundson, AB; Harris, DL; King, E; Ramsland, PA,
)
0.13
"AC hemizygous, p53 haploinsufficient, and Cdkn2a deficient mice to aspartame in dosed feed."( NTP report on the toxicology studies of aspartame (CAS No. 22839-47-0) in genetically modified (FVB Tg.AC hemizygous) and B6.129-Cdkn2atm1Rdp (N2) deficient mice and carcinogenicity studies of aspartame in genetically modified [B6.129-Trp53tm1Brd (N5) hap
, 2005
)
0.33
", disintegration profiles) of solid oral dosage forms."( Non-destructive determination of anisotropic mechanical properties of pharmaceutical solid dosage forms.
Akseli, I; Cetinkaya, C; Hancock, BC, 2009
)
0.35
" Altogether, our findings indicate that denatonium stimulates CASR by shifting a dose-response curve for the principal CASR agonist Ca(2+) to lower concentrations."( Stimulation of the extracellular Ca²⁺-sensing receptor by denatonium.
Bystrova, MF; Churbanov, GD; Kolesnikov, SS; Rogachevskaja, OA; Romanov, RA, 2011
)
0.37
" Since 1981, when aspartame was first approved by the US Food and Drug Administration, researchers have debated both its recommended safe dosage (40 mg/kg/d) and its general safety to organ systems."( Revisiting the safety of aspartame.
Choudhary, AK; Pretorius, E, 2017
)
0.46
"Researchers from the Ramazzini Institute have reported that lifespan dosing of rats with aspartame treatment is associated with an increased overall incidence of malignant tumors, including leukemias/lymphomas, transitional cell carcinomas of the renal pelvis/ureter, and malignant schwannomas of the peripheral nerves."( Histological analyses of the Ishii (1981) rat carcinogenicity study of aspartame and comparison with the Ramazzini Institute studies.
Fujitani, S; Iwata, H; Lynch, B; Roberts, A; Shibui, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
sweetening agentSubstance that sweeten food, beverages, medications, etc.
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
micronutrientAny nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
EC 3.1.3.1 (alkaline phosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of alkaline phosphatase (EC 3.1.3.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
carboxylic acidA carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
dipeptide zwitterionAny peptide zwitterion comprising two amino acid residues. Major structure at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Phenylalanine and tyrosine catabolism1131
Phenylalanine and tyrosine metabolism1132
Phenylalanine metabolism621

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
GLI family zinc finger 3Homo sapiens (human)Potency18.83360.000714.592883.7951AID1259369
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.58490.001318.074339.8107AID926; AID938
EWS/FLI fusion proteinHomo sapiens (human)Potency30.56580.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.58960.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency70.79460.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.22500.000229.305416,493.5996AID743069
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588537
aryl hydrocarbon receptorHomo sapiens (human)Potency11.96210.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency32.67050.001723.839378.1014AID743083
gemininHomo sapiens (human)Potency0.73080.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID235429Determined to achieve reproducible taste; +++ indicates ~80-200 times as sweet as sucrose1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Peptide sweeteners. 4. Hydroxy and methoxy substitution of the aromatic ring in L-aspartyl-L-phenylalanine methyl ester. Structure-taste relationships.
AID90239Sensory evaluation was done for sweetness at a concentration of 750 p.p.m. against compound potency calculated on weight basis.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID233335Sweet potency as logarithm of sweet potency (log SP) relative to sucrose1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Structure--sweetness relationship of L-aspartyl dipeptide analogues. A receptor site topology.
AID235569Evaluated for the quality of taste by acting at receptor site1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-taste correlation of L-aspartyl dipeptides using SIMCA method.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID235422Compound was evaluated for the potency of sweet taste when sweetness of sucrose is taken as 1 on a weight basis; 150-2001982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Peptide sweeteners. 5. Side-chain homologues relating zwitterionic and trifluoroacetylated amino acid anilide and dipeptide sweeteners.
AID89777Sensory evaluation was done for sweetness at a concentration of 750 p.p.m. against sample intensity relative to 10% sucrose.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID681802TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Aspartame: 1000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID90101Sensory evaluation was done for sweetness at a concentration of 750 p.p.m. against compound potency calculated on a molar basis. 1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID235425Determined to achieve reproducible taste; +++ indicates 80-200 times as sweet as sucrose1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Peptide sweeteners. 4. Hydroxy and methoxy substitution of the aromatic ring in L-aspartyl-L-phenylalanine methyl ester. Structure-taste relationships.
AID679538TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Aspartame: 200 uM) in OAT1-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID681038TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Aspartame: 200 uM) in OAT3-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID90408Sensory evaluation was done at a concentration of 750 p.p.m. against property of bitterness.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID233352Potency based on concentration of sweetener which matches the sweetness recognition threshold of sucrose (~2%)1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Genetically evolved receptor models: a computational approach to construction of receptor models.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID90407Sensory evaluation was done at a concentration of 750 p.p.m. against other properties.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID90409Sensory evaluation was done at a concentration of 750 p.p.m. against property of sweetness.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID680170TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Aspartame: 200 uM) in OAT4-expressing S2 cells2002Biochimica et biophysica acta, Jun-12, Volume: 1590, Issue:1-3
Role of human organic anion transporter 4 in the transport of ochratoxin A.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,031)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990239 (23.18)18.7374
1990's240 (23.28)18.2507
2000's192 (18.62)29.6817
2010's242 (23.47)24.3611
2020's118 (11.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials124 (11.20%)5.53%
Reviews104 (9.39%)6.00%
Case Studies31 (2.80%)4.05%
Observational1 (0.09%)0.25%
Other847 (76.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]